Arcturus Q3 net loss narrows to $6.9M; $25M milestone from KOSTAIVE first sale in Japan

Arcturus Therapeutics Holdings Inc.

2025-Q3 EPS reported -$1.89 vs consensus -$0.84 ▼ miss (-125.1%)

Q3 revenue $41.7M vs $45.2M YoY, down on lower CSL milestones; net loss $6.9M ($0.26/sh) vs $16.2M ($0.61/sh).
Cash $294.1M; runway extended through Q1 2027. Total $462.1M in upfront and milestone payments from CSL to date.
$25M commercial milestone triggered by first sale of KOSTAIVE in Japan by Meiji Seika Pharma in September.
ARCT-032 CF and ARCT-810 OTC deficiency Phase 2 interim proof-of-concept data expected in first half of 2025.
European CHMP opinion for KOSTAIVE expected December 2024; U.S. BLA filing planned in H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.